Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 4,159 Shares

Key Points

• Bruce Booth, a Kymera director, has sold multiple blocks of KYMR stock recently — including 4,159 shares on April 14 at $89.97 and an earlier 81,866‑share sale on March 2 (~$7.38M); the April trades were disclosed as part of a pre‑arranged Rule 10b5‑1 plan and reduced his position by 50%.
• Kymera shares fell about 3.2% to $86.14 after the company reported a Q miss (EPS -$0.97 vs. -$0.77 expected) and revenue down 60.8% YoY, but analysts remain largely positive with a consensus "Moderate Buy" and an average price target of $118.90.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bruce Booth sold 4,159 shares of the company's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $89.97, for a total value of $374,185.23. Following the completion of the transaction, the director directly owned 4,159 shares of the company's stock, valued at approximately $374,185.23. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.10, for a total transaction of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.95, for a total transaction of $197,890.00.
• On Monday, March 2nd, Bruce Booth sold 81,866 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.13, for a total value of $7,378,582.58.

Kymera Therapeutics Stock Down 3.2%

Kymera Therapeutics stock traded down $2.86 during mid-day trading on Thursday, hitting $86.14. 554,950 shares of the stock were exchanged, compared to its average volume of 732,626. The firm's fifty day simple moving average is $83.69 and its two-hundred day simple moving average is $74.15. Kymera Therapeutics, Inc. has a 12 month low of $24.72 and a 12 month high of $103.00. The stock has a market capitalization of $7.03 billion, a price-to-earnings ratio of -23.41 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same quarter last year, the company earned ($0.88) earnings per share. The company's quarterly revenue was down 60.8% compared to the same quarter last year. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYMR. Smartleaf Asset Management LLC boosted its holdings in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC raised its position in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after acquiring an additional 349 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics during the 4th quarter valued at $63,000. Bessemer Group Inc. increased its stake in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares during the period.

Analysts Set New Price Targets

Several research analysts have weighed in on KYMR shares. UBS Group upped their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a "buy" rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Piper Sandler raised their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, February 26th. Barclays lifted their price target on shares of Kymera Therapeutics to $133.00 and gave the stock an "overweight" rating in a report on Tuesday, January 27th. Finally, B. Riley Financial lifted their price objective on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a "buy" rating in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.